作为乳腺癌免疫治疗的潜在免疫检查点目标,TIGIT
Omer Qutaiba B Allela1, Abdulkareem Shareef2, Nasir Vadia3
1College of Pharmacy, Alnoor University, Mosul, Iraq. omerallela@alnoor.edu.iq.
Medical oncology (Northwood, London, England)
|August 5, 2025
概括
用Ig和ITIM域阻断T细胞免疫受体 (TIGIT) 在乳腺癌免疫疗法中显示出希望. 抑制TIGIT可以恢复免疫细胞功能,减少瘤,并增强抗癌反应.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 遗传学 是一个遗传学.
背景情况:
- 乳腺癌是全球领先的健康问题,每年有超过230万例.
- 复杂的起源涉及遗传突变 (例如BRCA1/2),荷尔蒙因素和生活方式的影响.
- 传统治疗正在发展,包括免疫疗法,准免疫逃避机制.
研究的目的:
- 审查T细胞免疫受体与Ig和ITIM域 (TIGIT) 在乳腺癌中的作用.
- 探索TIGIT的表达,预后价值和治疗潜力.
- 要突出TIGIT抑制如何克服乳腺癌中的免疫抑制.
主要方法:
- 对TIGIT在乳腺癌中的功能进行文献综述.
- 分析TIGIT在免疫逃避和瘤发生中的作用.
- 检查实验模型,证明TIGIT阻塞的有效性.
主要成果:
- 在T和NK细胞表达的TIGIT结合CD155,抑制免疫反应并促进瘤生长.
- 通过耗尽细胞毒性淋巴细胞并创建免疫抑制微环境,TIGIT促进癌症发生.
- 阻断TIGIT恢复NK和T细胞功能,导致瘤减少和增强免疫力.
结论:
- 紧张是乳腺癌进展中的重要免疫检查点.
- 抑制TIGIT是一种有前途的乳腺癌治疗策略.
- 向TIGIT可以破坏免疫抑制并改善抗瘤反应.
相关概念视频
Tumor Immunotherapy
658
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
658
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
The Tumor Microenvironment
6.8K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.8K
Cancer Vaccines
509
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
509
Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
TGF - β Signaling Pathway
7.6K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.6K


